Active Development
Drug Pipeline
10+ novel targets across Phase I-III clinical trials with breakthrough potential for oncology treatment.
0
Phase I
Safety & dosing trials
0
Phase II
Efficacy testing
0
Phase III
Pivotal trials
0
Preclinical
In development
Active Programs
Clinical Pipeline
Leading drug candidates across multiple therapeutic areas
Phase III
KRAS G12C
ONC-201: KRAS Inhibitor
First-in-class KRAS G12C inhibitor for NSCLC
Enrollment
30%
Phase I
CDK2
ONC-305: CDK2 Inhibitor
Selective CDK2 inhibitor overcoming CDK4/6 resistance in HR+ breast cancer.
Enrollment
60%
Phase I
BCL-XL
ONC-412: PROTAC Degrader
Targeted protein degradation approach for hematological malignancies with novel mechanism.
Enrollment
30%
Interested in Our Pipeline?
Learn more about partnership opportunities or request detailed pipeline information.